Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings.
Our operations are strategically located in:
Lincoln, Nebraska (Corporate Headquarters)
Philadelphia, Pennsylvania
Phoenix, Arizona
Belfast, Northern Ireland,UK
Zurich, Switzerland
Vienna, Austria
Richmond, Virginia
Montreal, Quebec, Canada
For more information, visit: www.celerion.com
Bioventus®Inc. (Nasdaq: BVS) develops Innovations for Active Healing and its mission is to make a difference by helping patients resume and enjoy active lives.
The Company has products focused in three vertical markets: pain treatment, restorative therapies and surgical solutions. Established in 2012, Bioventus is headquartered in Durham, NC. The company has more than 900 employees worldwide and its international headquarters is in Hoofddorp, The Netherlands.
Bioventus also has offices in Memphis, TN, Farmingdale, NY, Valencia, CA and Mississauga, Ontario, Canada.
Bioventus works with patients, payers and health care providers throughout the world; in more than 50 countries.
Visit www.Bioventus.com and find us on Twitter @bioventusglobal.